Potassium channels as novel molecular targets in hepatocellular carcinoma (Review)

Oncol Rep. 2023 Oct;50(4):185. doi: 10.3892/or.2023.8622. Epub 2023 Sep 1.

Abstract

Hepatocellular carcinoma (HCC) poses a serious health burden worldwide. It is often not diagnosed until the patient is at an advanced stage of the disease, when treatment options are limited and the prognosis is poor. Therefore, novel treatment strategies are urgently required. Potassium (K+) channels have an important role in HCC, including regulating the proliferation, migration, invasion and drug resistance of HCC cells. The aim of the present review was therefore to survey the relevant publications that have investigated K+ channels not only as markers for the early diagnosis of HCC, but also as potential therapeutic targets for the treatment of HCC. Several of these channels have been indicated to be the sites of action for natural products previously known to inhibit HCC; however, more systematic studies are required to determine which K+ channels may be utilized for the clinical treatment of HCC, particularly in the advanced stages of the disease and in cases where patients are resistant to the existing drugs.

Keywords: biomarker; hepatocellular carcinoma; potassium channel; therapeutic target.

Publication types

  • Review

MeSH terms

  • Biological Products*
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / genetics
  • Cell Line
  • Humans
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / genetics
  • Potassium Channels

Substances

  • Potassium Channels
  • Biological Products

Grants and funding

The present study was funded by the National Natural Science Foundation of China (grant no. 82073087), and the Collaborative Innovation Center of Chinese Ministry of Education (grant no. 2020-39).